Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESTANASDAQ:IRTCNASDAQ:PRCTNASDAQ:SLNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESTAEstablishment Labs$36.58-3.3%$34.76$26.56▼$52.41$1.09B0.74472,757 shs292,333 shsIRTCiRhythm Technologies$150.95+3.6%$132.19$55.92▼$151.01$4.65B1.4480,243 shs472,443 shsPRCTPROCEPT BioRobotics$58.74-2.5%$57.08$47.04▼$103.81$3.33B1.1834,664 shs441,314 shsSLNOSoleno Therapeutics$81.42+1.8%$75.45$36.93▼$83.07$4.03B-2.69771,914 shs1.04 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESTAEstablishment Labs-3.25%-5.99%-0.11%-11.98%-11.77%IRTCiRhythm Technologies+3.57%+4.24%+5.79%+41.60%+46.52%PRCTPROCEPT BioRobotics-2.46%-2.75%+2.37%-6.06%-1.97%SLNOSoleno Therapeutics+1.80%+4.18%+5.89%+62.68%+97.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationESTAEstablishment Labs2.5038 of 5 stars3.42.00.00.02.22.50.6IRTCiRhythm Technologies1.409 of 5 stars2.53.00.00.02.70.00.6PRCTPROCEPT BioRobotics2.5887 of 5 stars3.41.00.00.02.63.30.6SLNOSoleno Therapeutics4.7451 of 5 stars4.63.00.04.62.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESTAEstablishment Labs 2.80Moderate Buy$52.4043.25% UpsideIRTCiRhythm Technologies 2.90Moderate Buy$138.60-8.18% DownsidePRCTPROCEPT BioRobotics 2.86Moderate Buy$90.0053.22% UpsideSLNOSoleno Therapeutics 3.10Buy$107.1031.54% UpsideCurrent Analyst Ratings BreakdownLatest ESTA, SLNO, IRTC, and PRCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025SLNOSoleno TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$110.006/13/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$48.006/11/2025IRTCiRhythm TechnologiesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$130.00 ➝ $160.005/22/2025IRTCiRhythm TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $167.005/16/2025ESTAEstablishment LabsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$62.005/14/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$48.005/8/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$81.00 ➝ $97.005/8/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$102.00 ➝ $105.005/2/2025IRTCiRhythm TechnologiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$152.00 ➝ $139.005/2/2025IRTCiRhythm TechnologiesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$133.00 ➝ $150.005/2/2025IRTCiRhythm TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$104.00 ➝ $130.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESTAEstablishment Labs$170.24M6.21N/AN/A$1.90 per share19.25IRTCiRhythm Technologies$591.84M8.14N/AN/A$2.90 per share52.05PRCTPROCEPT BioRobotics$224.50M14.48N/AN/A$7.71 per share7.62SLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESTAEstablishment Labs-$84.60M-$3.10N/AN/AN/A-52.34%-196.25%-26.64%8/5/2025 (Estimated)IRTCiRhythm Technologies-$113.29M-$3.14N/AN/AN/A-15.90%-101.04%-9.55%7/30/2025 (Estimated)PRCTPROCEPT BioRobotics-$91.41M-$1.70N/AN/AN/A-36.20%-28.09%-20.02%7/30/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.62N/AN/AN/AN/A-77.52%-63.44%8/6/2025 (Estimated)Latest ESTA, SLNO, IRTC, and PRCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ESTAEstablishment Labs-$0.83-$0.70+$0.13-$0.70$41.15 million$41.38 million5/7/2025Q1 2025SLNOSoleno Therapeutics-$1.14-$0.95+$0.19-$0.95N/AN/A5/1/2025Q1 2025IRTCiRhythm Technologies-$0.89-$0.95-$0.06-$0.97$153.39 million$158.68 million4/24/2025Q1 2025PRCTPROCEPT BioRobotics-$0.49-$0.45+$0.04-$0.45$65.39 million$69.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthESTAEstablishment LabsN/AN/AN/AN/AN/AIRTCiRhythm TechnologiesN/AN/AN/AN/AN/APRCTPROCEPT BioRoboticsN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESTAEstablishment Labs5.723.362.05IRTCiRhythm Technologies7.475.715.58PRCTPROCEPT BioRobotics0.138.957.75SLNOSoleno Therapeutics0.2119.6419.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESTAEstablishment Labs72.91%IRTCiRhythm TechnologiesN/APRCTPROCEPT BioRobotics89.46%SLNOSoleno Therapeutics97.42%Insider OwnershipCompanyInsider OwnershipESTAEstablishment Labs11.09%IRTCiRhythm Technologies0.68%PRCTPROCEPT BioRobotics17.40%SLNOSoleno Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESTAEstablishment Labs1,01828.92 million25.61 millionOptionableIRTCiRhythm Technologies2,00031.92 million31.71 millionOptionablePRCTPROCEPT BioRobotics43055.33 million45.70 millionOptionableSLNOSoleno Therapeutics3050.39 million47.17 millionOptionableESTA, SLNO, IRTC, and PRCT HeadlinesRecent News About These CompaniesSoleno Therapeutics (NASDAQ:SLNO) Sets New 1-Year High - Here's What HappenedJune 23 at 4:49 PM | marketbeat.comSoleno Therapeutics initiated with a Buy at TD CowenJune 23 at 1:41 PM | msn.comFDA Approval for its Drug Lifted Soleno Therapeutics (SLNO) Shares by 60%June 23 at 1:41 PM | msn.comSoleno Therapeutics (NASDAQ:SLNO) Coverage Initiated at TD CowenJune 23 at 8:30 AM | marketbeat.comSoleno Therapeutics: Overbought On VYKAT Approval EnthusiasmJune 22 at 10:50 AM | seekingalpha.comGAMMA Investing LLC Increases Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)June 22 at 3:02 AM | marketbeat.comPiper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR ProspectsJune 20, 2025 | msn.comSoleno Therapeutics to Present Research Findings at 2025 International Prader-Willi Syndrome ConferenceJune 20, 2025 | quiverquant.comSoleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome ConferenceJune 20, 2025 | globenewswire.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Rating of "Buy" from BrokeragesJune 14, 2025 | marketbeat.com434,514 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Acquired by Assenagon Asset Management S.A.June 13, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Sets New 12-Month High - Here's What HappenedJune 12, 2025 | marketbeat.comThese 24 Stocks Are Ripe for a Short SqueezeJune 12, 2025 | schaeffersresearch.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Harbor Capital Advisors Inc.June 11, 2025 | marketbeat.comCalifornia State Teachers Retirement System Has $988,000 Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO)June 11, 2025 | marketbeat.comCantor Fitzgerald Comments on SLNO FY2026 EarningsJune 10, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 5,462 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)June 10, 2025 | marketbeat.comNuveen Asset Management LLC Has $2.84 Million Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)June 3, 2025 | marketbeat.comWellington Management Group LLP Grows Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO)June 1, 2025 | marketbeat.comAmeriprise Financial Inc. Increases Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)June 1, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Polar Asset Management Partners Inc.May 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeChime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the StrengthDarden Stock Set to Sizzle After Blowout Q4 and $1B BuybackBy Thomas Hughes | June 23, 2025View Darden Stock Set to Sizzle After Blowout Q4 and $1B BuybackESTA, SLNO, IRTC, and PRCT Company DescriptionsEstablishment Labs NASDAQ:ESTA$36.58 -1.23 (-3.25%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$36.60 +0.02 (+0.05%) As of 06/23/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.iRhythm Technologies NASDAQ:IRTC$150.95 +5.21 (+3.57%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$151.26 +0.31 (+0.21%) As of 06/23/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.PROCEPT BioRobotics NASDAQ:PRCT$58.74 -1.48 (-2.46%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$59.76 +1.02 (+1.74%) As of 05:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.Soleno Therapeutics NASDAQ:SLNO$81.42 +1.44 (+1.80%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$83.07 +1.65 (+2.03%) As of 06:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
